GlassScriptPhysician profile
Annu Gupta
NPI 1972944817
$5,196.36
in general payments reported to CMS, 2019-2025
26 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $1,392 · 2023: $749 · 2024: $1,430 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,389.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,892.42 | 2021-2025 | |
| Janssen Biotech, INC. | $580.83 | 2022-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.11 | 2022-2025 | Xifaxan, Trulance |
| Celgene Corporation | $283.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.55 | 2021-2025 | Gattex, Entyvio, Eohilia |
| Gilead Sciences, INC. | $217.88 | 2021-2025 | |
| Qol Medical, LLC | $177.02 | 2022-2024 | Sucraid |
| Aimmune Therapeutics, INC. | $173.64 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $131.24 | 2024-2025 | Voquezna |
| Genzyme Corporation | $125.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $114.04 | 2021-2022 | |
| Ardelyx, INC. | $101.12 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $90.66 | 2023-2025 | Omvoh |
| Intuitive Surgical, INC. | $85.90 | 2023 | Da Vinci Surgical System |
| Regeneron Healthcare Solutions, INC. | $74.26 | 2022-2025 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $64.02 | 2022 | |
| Pfizer INC. | $63.07 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $62.34 | 2022-2024 | Linzess |
| Madrigal Pharmaceuticals | $43.96 | 2025 | Rezdiffra |
| Novo Nordisk INC | $24.19 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $23.40 | 2021 | |
| Enterra Medical, INC. | $20.00 | 2024 | |
| Daiichi Sankyo INC. | $19.96 | 2022 | |
| Braintree Laboratories, INC. | $18.60 | 2025 | Suflave |
| Ipsen Biopharmaceuticals, INC | $16.79 | 2025 | Iqirvo |
| Vivus LLC | $15.05 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.